US-based healthtech company Eko Health on Wednesday announced that it raised $41 million in Series D financing to scale artificial intelligence (AI)-driven heart and lung disease detection.
The round was led by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital. The funding will also be used to expand US and global access to the company’s early disease detection platform.
“Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices,” Connor Landgraf, CEO and co-founder of Eko Health, said in a statement.
Moreover, the company said that the funding builds on recent commercial and clinical milestones, including US Food and Drug Administration (FDA) clearances for its structural heart murmur and low ejection fraction (Low EF) detection algorithms.
“Eko has spent the past decade building an unparalleled dataset of digital heart and lung sounds, which it leverages to develop clinical AI for the physical world,” said Vas Bailey, PhD, Chair of the Board at Eko Health and Partner at ARTIS Ventures.
Cardiovascular and pulmonary diseases are among the leading causes of death globally, underscoring the critical need for early detection. Millions of patients remain unaware of their risk factors, often due to limited access to effective detection tools.
Eko is addressing this gap by introducing sophisticated detection capabilities into any physical exam — from primary care exams at NCH Healthcare System in the US to maternal-fetal health exams in Nigeria, the company mentioned.